AMARIN CORP PLC\UK (AMRN): Results of Operations and Financial Condition
AMARIN CORP PLC\UK (AMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash
How this was made
The 30-second read
Why it matters
The filing combines quantified financial performance (revenue decline, major opex reduction, cash increase, debt-free) with operational traction (partner-network in-market demand growth, U.S. IPE market share at 48%, and Europe availability in 11 countries). It also reiterates FY 2026 expectations for international growth, U.S. market share maintenance, improved opex profile, and positive cash flow generation.
Market read
Traders can update AMRN’s near-term valuation assumptions around cost trajectory, cash generation, and the pace of international adoption under the Recordati partnership, while monitoring ongoing U.S. pricing pressure from generics.
What to watch
International comparisons are expected to start in Q3 2026 under the Recordati partnership model, so near-term revenue optics may be structurally distorted versus prior-year periods.
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Operating expenses and net loss declined materially, cash increased and global in-market demand grew, but total net revenue declined 42% and total product revenue declined 16%, with U.S., Europe and Rest-of-World product revenue all lower year over year.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q2 2026 Total Net Revenueother | $42.2 million | – | (42)% |
| 1H 2026 Total Net Revenueother | $87.3 million | – | (24)% |
| Q2 2026 Total Product Revenue, netother | $39.1 million | – | (16)% |
| 1H 2026 Total Product Revenue, netother | $82.4 million | – | (6)% |
| Q2 2026 Licensing & Royaltiesother | $3.1 million | – | (88)% |
| 1H 2026 Licensing & Royaltiesother | $4.9 million | – | (82)% |
| Q2 2026 COGSother | $27.2 million | – | 22% |
| 1H 2026 COGSother | $54.6 million | – | 39% |
| Q2 2026 SG&Aother | $22.2 million | – | (43)% |
| 1H 2026 SG&Aother | $43.3 million | – | (42)% |
| Q2 2026 R&Dother | $4.8 million | – | (3)% |
| 1H 2026 R&Dother | $9.4 million | – | (8)% |
| Q2 2026 Restructuringother | -- | – | NM |
| 1H 2026 Restructuringother | $3.4 million | – | (85)% |
| Q2 2026 Total Operating Expensesother | $27.0 million | – | (59)% |
| 1H 2026 Total Operating Expensesother | $56.1 million | – | (48)% |
| Q2 2026 Operating Lossother | $(12.0) million | – | 25% |
| 1H 2026 Operating Lossother | $(23.3) million | – | 29% |
| Q2 2026 Operating Margin %other | (28)% | – | (6) pts |
| 1H 2026 Operating Margin %other | (27)% | – | 2 pts |
| Q2 2026 Net Lossother | $(7.7) million | – | 46% |
| 1H 2026 Net Lossother | $(18.2) million | – | 39% |
| Q2 2026 Net Marginother | (18)% | – | 1 pts |
| 1H 2026 Net Marginother | (21)% | – | 5 pts |
| Cash as of June 30, 2026other | $314.6 million | – | 5% |
| U.S. IPE market share in Q2 2026other | 48% | – | – |
| VASCEPA branded prescriptions in Q2 2026other | 14% | – | 14% |
| Global partner-network in-market demand in Q2 2026other | 59% | – | 59% |
| China in-market volume in 1H 2026other | 90% | – | 90% |
| Europe VAZKEPA in-market demand in Q2 2026other | 69% | – | 69% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. Product Revenue, netA modest decline in U.S. sales of VASCEPA was driven by continued generic competition in the IPE market and the resulting pressure on net pricing, partially offset by increased demand for branded VASCEPA. | $32.2 million | – | (12)% |
| Europe Product Revenue, netA slight decline in European revenue was attributable to moving to a partnered sales model beginning in the second half of 2025. | $5.4 million | – | (17)% |
| Rest-of-World Product Revenue, netRevenue was reflective of normal variability in partner purchasing patterns and the timing of shipments across multiple geographies. | $1.4 million | – | (61)% |
| Licensing & RoyaltiesLower licensing and royalty revenue reflected the Recordati payment received in last year's second quarter, partially offset by royalties from the Recordati agreement in the current quarter. | $3.1 million | – | (88)% |
FY 2026 outlook
- NoteThe Company expects cash to grow by approximately 10% as of December 31, 2026 compared to December 31, 2025.
- NoteThe Company expects that U.S. volumes will remain consistent throughout FY 2026.
- NoteThe Company expects combined in-market demand across all its global partner markets to continue to grow.
What drove it
- Across the global partner network, in-market demand for VASCEPA/VAZKEPA rose by 59% in Q2 2026 compared to Q2 2025.
- In-market demand in Europe for VAZKEPA rose by 69% in Q2 2026 from Q2 2025.
- The Company’s share of the U.S. IPE market increased to 48% in Q2 2026 compared to 43% in Q2 2025.
- Operating expenses declined by $39.3 million, or 59% compared to Q2 2025, in line with the completed $70 million annual cost savings initiative.
- SG&A decreased 43% to $22.2 million, reflecting a reduction in costs associated with the Global Restructuring Plan.
Concerns
- Total net revenue declined to $42.2 million, primarily because Q2 2025 included a $25 million up front payment associated with the commencement of the Recordati agreement and there was no such payment in Q2 2026.
- Total product revenue, net declined 16%, while U.S., Europe and Rest-of-World product revenue each declined year over year.
- Continued generic competition in the IPE market created pressure on U.S. net pricing.
- COGS increased $4.8 million, or 22%, reflecting increased product volumes on which revenue was recognized during the period.
- Operating margin was (28)% in Q2 2026 compared to (22)% in Q2 2025.
What to watch
- Whether U.S. volumes remain consistent throughout FY 2026 amid generic competition and net-pricing pressure.
- Growth in combined in-market demand across global partner markets.
- Pricing, reimbursement, market access and adoption across additional countries within Recordati’s licensed territory.
- Anticipated near-term commercialization progress in Singapore and South Korea.
- Cash growth by approximately 10% as of December 31, 2026 compared to December 31, 2025.
Balance sheet and cash flow
- Cash as of June 30, 2026 was $314.6 million, compared to $302.6 million at December 31, 2025.
- Cash as of June 30, 2026 was $314.6 million, compared to $298.7 million in Q2 2025.
- Inventories as of June 30, 2026 declined by $19.5 million from March 31, 2026 and by $31.8 million from December 31, 2025.
- The Company remained debt free as of June 30, 2026.
- The Company generated positive cash flow for the third consecutive quarter.
Analysis
Amarin reported Q2 2026 total net revenue of $42.2 million, down 42% from $72.7 million. The principal comparison item was the $25 million up front payment tied to the commencement of the Recordati agreement in Q2 2025, which did not recur. Total product revenue, net was also lower at $39.1 million, down 16%, showing that the year-over-year revenue decline was not solely a licensing comparison issue.
U.S. product revenue, net was $32.2 million, down 12%, as generic competition in IPE and associated net-pricing pressure more than offset increased demand for branded VASCEPA. The commercial indicators were stronger than the reported U.S. revenue trend: VASCEPA branded prescriptions rose by 14% and the Company's U.S. IPE market share increased to 48% from 43%. International in-market demand also advanced, rising 59% across the global partner network, 69% in Europe and 90% year to date in China, while reported Europe and Rest-of-World revenue remained lower under the transition to the partnered commercial model and shipment-timing variability.
Cost actions were the central financial offset. Total operating expenses were $27.0 million, down 59%, and SG&A was $22.2 million, down 43%. Management said the $70 million annual cost savings initiative is complete, and restructuring charges associated with the Global Restructuring Plan were immaterial in Q2 2026. COGS increased 22% to $27.2 million, reflecting increased product volumes on which revenue was recognized. Operating loss improved to $(12.0) million and net loss improved to $(7.7) million, though operating margin was (28)% versus (22)% in Q2 2025.
Liquidity improved during the period. Cash was $314.6 million at June 30, 2026, compared with $302.6 million at December 31, 2025, and the Company remained debt free. Inventories declined by $19.5 million from March 31, 2026 and by $31.8 million from December 31, 2025. The Company also reported positive cash flow for the third consecutive quarter.
For FY 2026, Amarin expects U.S. volumes to remain consistent, combined in-market demand across global partner markets to continue to grow, and cash to grow by approximately 10% as of December 31, 2026 compared to December 31, 2025. Execution points are adoption and reimbursement expansion across Recordati's territory, where VAZKEPA was commercialized in 11 European countries as of June 30, 2026, and progress toward anticipated near-term commercialization in Singapore and South Korea.
Management, verbatim
The strategic actions we have taken are driving stronger results and a path to sustained growth and profitability.
Aaron Berg, President and Chief Executive Officer
We have established a materially lower operating expense baseline to support our global sales initiatives and position the Company to generate revenues more profitably than under our former model.
Peter Fishman, Chief Financial Officer
Not in the filing
stated, not guessed- GAAP or non-GAAP designation for the reported financial metrics was not stated in the provided release.
- Gross profit and gross margin were not reported.
- Earnings per share, diluted share count and adjusted or non-GAAP earnings metrics were not reported.
- Operating cash flow and free cash flow amounts were not reported.
- The amount of positive cash flow reported for the third consecutive quarter was not reported.
- Cash balance as of March 31, 2026 was not reported.
- Inventory balance as of June 30, 2026 was not reported.
- Debt amount was not reported.
- Share repurchases, dividends and other capital-return figures were not reported.
- Prior-quarter values and quarter-over-quarter changes for the reported revenue, expense, profit and margin metrics were not reported.
- Numeric FY 2026 revenue, gross-margin, operating-expense and tax-rate guidance was not reported.
- No prior outlook section was provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Amarin’s Q2 2026 8-K centers on results and the one-year anniversary of its exclusive long-term Recordati license and supply agreement to commercialize VASCEPA/VAZKEPA across 59 Europe-focused countries.
Ticker impact
Amarin reported Q2 2026 results, including total net revenue of $42.2M, operating expenses down 59% YoY, and $314.6M cash with no debt.
Likely supportive for AMRN near term, given the large opex reduction, positive cash flow commentary, and reiterated FY 2026 expectations.
This is a primary SEC 8-K with quantified financials and specific operational metrics (in-market demand growth, U.S. market share, cash balance, debt-free). However, revenue declined YoY and the international model is still early, which can temper the reaction.
Market effects
Signals potential margin and cash-flow improvement for cardiovascular pharma players using partnered commercialization models, with read-across to IPE/VASCEPA competitive dynamics.
Highlights Europe and Asia adoption progress (Recordati territory, China and Europe demand growth), which may influence regional sentiment for cardiovascular therapeutics.
Reinforces that IPE commercialization outside the U.S. is progressing via licensing partnerships, affecting how investors price global expansion timelines.
Counterpoint
Despite opex and cash improvements, total net revenue fell 42% YoY to $42.2M, and U.S. product revenue was down 12% YoY due to generic pricing pressure.
Key entities
- companyAmarin Corporation plc
NASDAQ-listed cardiovascular therapeutics company reporting Q2 2026 financial results and partnered international commercialization progress.
- partnerRecordati S.p.A.
Exclusive long-term license and supply partner for VASCEPA/VAZKEPA commercialization across Europe-focused territories.
- productVASCEPA/VAZKEPA (icosapent ethyl)
Amarin’s IPE therapy whose in-market demand and market share metrics are cited as key operational indicators.
